Chronic lymphocytic leukemia (CLL) is a cancer of the blood and bone marrow that has seen many changes in the way it is viewed and treated due to recent scientific research. Several targeted therapies have been developed and evaluated to treat CLL by attacking specific proteins that help leukemia cells to grow and survive. Often these targeted therapies are used in combination with other treatments, including more traditional forms of cancer therapy, and in some cases may help in disease control.
As with many diseases, continued research in CLL is necessary in order to better treat patients, possibly remove side effects of treatment and improve overall quality of life of the patient. Current treatments of CLL include the use of targeted therapy as well as traditional methods of treating the disease such as combination therapy. Some patients may be managed with active surveillance until treatment becomes necessary. As well as these treatment options, many clinical trials are currently being conducted in hopes to evaluate new ways to treat the disease and to improve current methods of treatment.
Moving Beyond Traditional Chemotherapy
Before targeted therapies, the traditional mainstay of CLL therapy has been chemotherapy, which can kill rapidly dividing cells. Many targeted therapies interfere with specific signals required for leukemia cells to divide and survive.
BTK inhibitors are the class of medicines that target Bruton’s tyrosine kinase, BTK, which is a critical component of B cell signaling for growth and survival. For CLL patients, ibrutinib acalabrutinib and Zanubrutinib are currently approved for certain patients.
On the other hand, the BCL-2 protein plays a crucial role in the survival of certain leukemia cells. By preventing these cells from undergoing apoptosis, normal cell death, the leukemia cells are able to continue to grow and multiply. A particular approach for treating CLL is to block the function of the BCL-2 protein in order to eliminate the leukemia cells. The drug venetoclax has been shown to accomplish this.
More Personalized Treatment Decisions
Each case of CLL is different and so can be treated by different methods and in combination with other treatments. Most cases of CLL are diagnosed after the cancer has progressed and treatments can be used to control the growth of the leukemia cells and to provide symptom relief.
Genetic or molecular changes can influence therapeutic decisions. Chromosome 17p deletion, a TP53 mutation and IGHV mutation status are examples of genetic and/or molecular features that are used to classify CLL cases for treatment purposes and take into account patients’ clinical presentation, previous therapy, age and general status of health and presence of other medical conditions.
New Options After Previous Treatment
Additionally, a range of treatments are currently under investigation for use following relapse of CLL following previous treatment.
Jaypirca (pirtobrutinib) is a non-covalent BTK inhibitor that binds to BTK in a non-covalent manner. Pirtobrutinib was approved by the U.S. Food and Drug Administration in December 2025 for the treatment of adults with Relapsed or Refractory CLL/SLL following at least one prior treatment with a covalent BTK inhibitor.
By targeting CLL using different mechanisms of action, new treatment options are being evaluated in patients whose disease is progressing on prior targeted therapies. A number of treatments are currently being investigated for use in this setting.
Combining Treatments in New Ways
Another area that the scientific and medical communities are currently researching is that of using a combination of different targeted leukemia treatments in order to attack the leukemia cells by more than one route.
This combination was approved by the FDA on February 26, 2026, for use in treating adults with CLL or SLL. Approval for this combination was based on results from the AMPLIFY study that included patients with previously untreated CLL or SLL who did not have del(17p) or TP53 mutation. More work is also being done to understand the length of treatment required for patients and whether some patients would benefit from certain treatments.
Clinical Trials and Future Therapies
For the time being, many novel approaches are being studied in clinical trials, including new cancer drugs, their combinations as well as sequences of treatments.
Researchers are studying novel combinations of targeted therapies including BTK inhibitors and BCL-2 inhibitors. Examples of current investigations include the combination of venetoclax and Zanubrutinib and other investigational BTK inhibitors.
There are also many on-going clinical trials of new chronic lymphocytic leukemia treatments. These may be of value to individual patients who meet specific eligibility criteria (e.g. those with a specific type and stage of leukemia or prior treatment). Eligibility for clinical trials must be discussed with the healthcare team.
Managing Treatment and Quality of Life
Managing the side effects of cancer treatment and ensuring that patients maintain their best quality of life are also primary objectives of modern cancer therapy.
Patients may consider making a list of medications, including prescription, over-the-counter products, and nutritional supplements, and inform the healthcare provider about any new symptoms. Different treatments have different side effects. Some can cause serious health problems like infections, decreased blood counts, gastrointestinal problems, and bleeding, while others may cause problems like blood clots, high blood pressure, or liver damage.
A number of chronic medical conditions can impact CLL treatment and must be managed by the doctor. The heart, kidneys, liver and other organs can be affected by previous illnesses and must be taken into consideration when choosing a treatment and monitoring the patient for side effects.
Looking Ahead
As understanding of chronic lymphocytic leukemia (CLL) continues to evolve, and as investigational therapies progress through clinical development, additional treatment approaches may become available. Researchers are working to develop treatments and find the right combination to use in different circumstances. For example, some patients may have CLL but may not need to be on any treatment and can be monitored instead. Others may have symptoms related disease or have CLL that is progressing and requires treatment.
Understanding treatment options and expressing treatment preferences to the doctor is important. Multiple treatments are currently being studied. Researchers are evaluating treatments to better understand their effectiveness, side effects, morbidity and impact on patients’ quality of life.
Medical Disclaimer: The information provided in this article is intended for educational purposes only and should not be interpreted as medical advice, clinical guidelines, or a recommendation for any specific treatment.